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Background Symptomatic patients with significant left ventricular systolic dysfunction (LVSD) require a tailored treatment ap-
proach. Both functional mitral regurgitation (FMR) and left bundle branch block (LBBB) can develop, contributing
to clinical deterioration, and worse prognosis despite optimal medical therapy (OMT).
...................................................................................................................................................................................................
Case summary We report the case of a symptomatic 60-year-old man on OMT with LVSD and significant FMR. His symptoms
and FMR initially improved following transvenous mitral annuloplasty using the CarillonVR Mitral Contour SystemVR
annuloplasty device. However, he subsequently developed LBBB with associated reduction in exercise capacity, for
which he underwent cardiac resynchronization therapy, and ensuing symptom improvement and stabilization.
...................................................................................................................................................................................................
Discussion Our case describes how targeted device interventions can be combined synergistically to optimize patient
symptoms.
                                                                                                                                                                                                                   
Keywords Cardiac resynchronization therapy • Heart failure • Mitral annuloplasty • Carillon • Functional mitral
regurgitation • Case report
Learning points
• Functional mitral regurgitation and left bundle branch block are frequently present in patients with symptomatic severe left ventricular sys-
tolic dysfunction despite guideline-based optimal medical therapy, and pathways of care should be responsive to changing clinical
circumstances.
• Cardiac resynchronization therapy (CRT) in accordance with current heart failure/CRT guidelines remains technically achievable in the
presence of a CarillonVR Mitral Contour SystemVR annuloplasty device and can be accomplished as a day-case under local anaesthetic using
standard techniques and equipment.
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Functional mitral regurgitation (FMR) is a common finding in cardio-
myopathy patients with both ischaemic and non-ischaemic left ven-
tricular systolic dysfunction (LVSD),1 being associated with worse
symptoms and higher morbidity and mortality. The mitral valve is
usually structurally normal, but ventricular (or atrial) dilatation or
associated regional wall motion abnormalities can result in lateral dis-
placement and mitral leaflet mal-coaptation leading to secondary
(functional) mitral regurgitation (MR). The development of left bun-
dle branch block (LBBB) can cause additional detriment, with cardiac
resynchronization therapy (CRT) being a well-established recom-
mended treatment, improving both symptoms and prognosis.2
Timeline
Case presentation
Chief complaint
A 60-year-old man with known heart failure with reduced ejection
fraction (HFrEF) presented to Heart Failure Clinic in January 2019
with worsening symptoms of shortness of breath, new orthopnoea,
and marked reduction in exercise tolerance [symptoms graded as
Class 3 of the New York Heart Association Functional Classification
of Heart Failure (NYHA III)], despite being on optimal guideline-
based pharmacological therapy2 at the highest tolerated doses, con-
sisting of Bisoprolol 5 mg b.i.d., Sacubitril/Valsartan 200 mg b.i.d.,
Spironolactone 25 mg o.d., and Bumetanide 5 mg o.d. Other regular
medications consisted of Aspirin 75 mg o.d., Atorvastatin 40 mg o.d.,
and Metformin 1 g b.i.d. Additionally, a recent increase in loop diuret-
ic dosage had exacerbated his gout symptoms. Physical examination
revealed new pulmonary and peripheral oedema, with increased
jugular venous pressure. Radial pulse was regular at 60 b.p.m., with a
blood pressure of 100/70.
Past medical history
Past medical history included dilated cardiomyopathy, non-ST-eleva-
tion myocardial infarction (diagnosed following presentation with
troponin-positive chest pain and an angiogram revealing moderate
diffuse coronary artery disease), Type 2 diabetes mellitus, obesity
....................................................................................................................................................................................................................
Date Events
June 2013 Diagnosed with dilated cardiomyopathy. Symptoms stable on Bisoprolol 10 mg o.d., Ramipril 10 mg o.d., Spironolactone
25 mg o.d.
May 2017 Presented acutely with chest pain and shortness of breath. Diagnosed as non-ST elevation myocardial infarction and heart failure
exacerbation.
Coronary angiogram: moderate diffuse coronary artery disease
Transthoracic echocardiogram: mild-moderate eccentric mitral regurgitation (MR), severe left ventricular (LV) dilatation, and
severe global left ventricular systolic dysfunction (LVSD)
Managed medically
November 2017 Seen in Heart Failure Clinic. Symptoms stable on optimized medical therapy (Bisoprolol 10 mg o.d., Sacubutril/Valsartan 200
mg b.i.d., Spironolactone 25 mg o.d., Ivabradine 5 mg b.i.d., Furosemide 80 mg o.d.). New York Heart Association (NYHA)
Class II
July 2018 Seen in Heart Failure Clinic. Worsening shortness of breath and orthopnoea, NYHA III/IV. Furosemide switched to Bumetanide
5 mg o.d.
Transthoracic echocardiogram: moderate eccentric MR, severe LV dilatation, and severe global LVSD.
12-lead electrocardiogram (ECG): sinus rhythm, heart rate 65 b.p.m., QRS 110 ms
Transoesophageal echocardiogram: severe eccentric MR
August 2018 Community heart failure nurse review. Remains symptomatic with significant orthopnoea, paroxysmal nocturnal dyspnoea, and
peripheral oedema. Increased diuretics caused worsening of gout symptoms. Remains NYHA III/IV
September 2018 CarillonVR Mitral Contour SystemVR annuloplasty device implant as part of REDUCE-FMR trial
October 2018 Seen in Heart Failure Clinic. Improvement in symptoms and NYHA II. Clinically euvolaemic
January 2019 Seen in Heart Failure Clinic with worsening symptoms, peripheral and pulmonary oedema, and NYHA III/IV
12-lead ECG: sinus rhythm, left bundle branch block (LBBB), and QRS 142 ms
February 2019 Echocardiogram: mild MR, severe LV dilatation, and severe global LVSD
March 2019 Remains symptomatic with reduced exercise tolerance, NYHA III
12-lead ECG: sinus rhythm, PR interval 178 ms, LBBB, and QRS 148 ms
April 2019 Cardiac resynchronization therapy with primary prevention defibrillator implanted
June 2019 Symptomatic improvement, clinically euvolaemic, and NYHA II
2 H.A. Jamil et al.
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..(body mass index 39), gout, and CarillonVR Mitral Contour SystemVR
annuloplasty device implantation as part of the REDUCE-FMR trial3
in September 2018.
Investigations
Echocardiogram (February 2019, Figure 1B) showing severe LVSD
and mild MR (previously moderate-severe on transthoracic and
transoesophageal echocardiograms in July 2018, prior to CarillonVR
device implant, Figure 1A; Supplementary material online, Video S1),
known moderate diffuse coronary artery disease on coronary angio-
gram (2017), sinus rhythm with new LBBB on electrocardiogram
(QRS duration 142 ms in January 2019, previously 110 ms in 2018).
Differential diagnosis
His current deterioration in symptoms was deemed to be the result
of developing LBBB with severe LVSD, despite initial symptomatic
improvement following CarillonVR device implant and optimal medical
therapy (OMT).
Management
A decision was made to implant a CRT with primary prevention de-
fibrillator (CRT-D) device, in accordance with the ESC guidelines on
Cardiac Pacing and CRT.4
Procedure
The patient attended for CRT-D implantation in April 2019. The pro-
cedure was carried out under local anaesthetic and aseptic technique
using a standard left infraclavicular incision and subclavian venous ac-
cess. Using routine lead-placement procedures, a Medtronic 6947M
internal cardioverter defibrillator dual-coil lead was positioned at the
right ventricular apex and a Medtronic 5076 active lead was posi-
tioned in the right atrial wall with good variables.
The coronary sinus (CS) was cannulated using a standard pre-
shaped CS guiding catheter (Attain system, Medtronic Inc.,
Minneapolis, MN, USA) with a standard MultiPurpose catheter.
Retrograde contrast fluoroscopy revealed a large lateral vein
(Figure 2A, Supplementary material online, Video S2). A 4798-78 cm
Medtronic left ventricular (LV) quadripolar lead was positioned in a
stable mid-lateral position (Figure 2B).
Follow-up
The patient was discharged the same day uneventfully and was
reviewed one week later in the pacing clinic for pacemaker param-
eter interrogation and incision area evaluation, with no issues identi-
fied. He has also reported a reduction in shortness of breath and
resolution of orthopnoea symptoms on telephone consultation re-
view with the HF specialist nursing team at 2 weeks; and was deemed
to have a symptom burden of NYHA Class II when reviewed in the
Heart Failure Clinic in June 2019 (see Timeline).
Discussion
Guideline-based OMT can improve LV systolic function, reduce
MR severity, and increase exercise capacity.1 In those with conduc-
tion delay, CRT is a well-established recommended treatment,
improving FMR, symptoms, and prognosis.3,5 For patients without
a traditional CRT indication, surgical correction of FMR is not
associated with improved outcomes.6 This has led to an increasing
drive to find percutaneous techniques to reduce the FMR, with
low peri-procedural risk.7 Recent trials have heightened anticipa-
tion that such percutaneous approaches might improve both
symptoms and outcomes.2,8
Percutaneous mitral annuloplasty using the CarillonVR device is a
fully transvenous approach utilizing the anatomical proximity of the
Figure 1 (A and B) Echocardiogram colour Doppler demonstrating the degree of mitral regurgitation prior to CarillonVR Mitral Contour SystemVR
implant (A) and on repeat study in 2019 when symptoms deteriorated (B).
CRT with previous mitral annuloplasty device 3
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..CS to the mitral ring, that can lead to clinically relevant reductions
in FMR.3 The device consists of distal and proximal anchors linked
by a flexible nitinol bridge which, when deployed within the CS,
can reduce FMR by externally restricting the mitral annulus
diameter.3,9
However, HFrEF is a progressive disease process, one feature of
which is the development of new conduction abnormalities.10
Observational studies have described an incidence of new-onset
LBBB of up to 10% at 1 year even in ostensibly stable patients.11
New intraventricular conduction delay and QRS prolongation are
associated with increased symptoms, worsening LV function, accel-
erated remodelling, increased risk of ventricular arrhythmias and
sudden death and are an independent risk factor for all-cause mor-
tality.12,13 The presence of LBBB also predicts lower rates of re-
verse remodelling,14 and intraventricular conduction delay,
especially LBBB is associated with worse FMR by lengthening LV
isovolumetric contraction and relaxation. There is no evidence
from observational studies or trials suggesting that device-based
treatments for FMR are associated with the development of intra-
ventricular delay or conduction abnormalities. Thus, our interpret-
ation was that the development of new LBBB reported, in this
case, is in keeping with the observed natural history of the under-
lying disease process.
There have been very few cases of CRT implantation in the pres-
ence of a CarillonVR Mitral Contour SystemVR annuloplasty device.15–18
The first reported case series by Hoppe et al. demonstrated the feasi-
bility of successful CRT after percutaneous mitral annuloplasty, while
in the other reported cases, the patients had pre-existing LBBB and
ongoing symptoms following CarillonVR device implant.
Several concerns arise when contemplating LV lead implantation
through the CarillonVR device, particularly around CS cannulation due
to altered geometry and increased tortuosity or angulation. Other
potential questions around lead positioning and stability and the risks
of CS dissection have been raised.6 In practice, as can be seen from
our image (Figure 1), the CarillonVR device provides easy visualization
of the CS anatomy and orientation, facilitating direct access.
Furthermore, tension from the device also reduces any tortuosity or
angulation at the ostia of tributaries, potentially increasing the ease of
LV lead placement. The conceivable risk of dislodgement of the
Carillon system can be disregarded since intravascular-ultrasound
data have demonstrated complete endothelialization of the anchors
of the Carillon device within 6 months of implant.10
Placing a CarillonVR Mitral Contour SystemVR over an existing trans-
venous CRT lead is currently not recommended, although a series of
animal experiments demonstrated the feasibility and stability of the
CarillonVR Mitral Contour SystemVR implanted in the presence of LV
leads, and also that these leads could be extracted without migration
of the CarillonVR device and without acute or long-term vascular
complications.19
Conclusion
This case highlights the complexity of caring for a patient with
symptomatic HFrEF, and that pathways of care should be respon-
sive to changing clinical circumstances. We have demonstrated
that a transvenous quadripolar LV lead can be safely implanted in
the presence of a CarillonVR Mitral Contour SystemVR using
Figure 2 (A and B) Retrograde venography demonstrating potential tributaries of the coronary sinus and the CarillonVR Mitral Contour SystemVR
(A) and the final position of the left ventricular lead (B).
4 H.A. Jamil et al.
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.standard implanting techniques under local anaesthetic as a day-
case procedure.
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